Pulmonary vascular disease & thromboembolism
Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site
Authors' conclusion
Cancer-associated UEDVT carries higher risks of recurrence and bleeding than noncancer UEDVT. Lung cancer showed the greatest recurrence during treatment. Anticoagulation beyond 90 days was associated with a lower post-treatment recurrence.
Study context
- Population
- Patients with objectively confirmed upper extremity DVT in the RIETE registry2,210 with cancer
- Participants
- 5,195 patients
- Exposure
- Cancer vs no cancer in upper extremity deep vein thrombosis (UEDVT)
- Cancern = 2,210
- Outcome
- Recurrent VTE and bleeding
- Follow-up
- 24 months
Methodological detailsinternational, observational registry
- International
- Observational registry
Main finding
As reported in the abstract
Cumulative incidence of recurrent VTE and bleeding
| Group | Recurrent venous thromboembolism (VTE) | Bleeding |
|---|---|---|
| Cancer | 3.9% (95% CI: 3.1-4.9) | 6.8% (95% CI: 5.7-8.1) |
| No cancer | 2.5% (95% CI: 1.8-3.5) | 4.3% (95% CI: 3.4-5.3) |
Recurrent venous thromboembolism (VTE)
Cancer3.9% (95% CI: 3.1-4.9)
No cancer2.5% (95% CI: 1.8-3.5)
Bleeding
Cancer6.8% (95% CI: 5.7-8.1)
No cancer4.3% (95% CI: 3.4-5.3)
Observational data: associations, not effects.
Further findings
Factors associated with recurrence during anticoagulation
| sHR (95% CI) | ||
|---|---|---|
| Lung cancer | 10.1 (1.31–78.06) | |
| 0.050.21520Subdistribution hazard ratio (log scale) |
| Outcome | sHR (95% CI) | |
|---|---|---|
| Factors associated with recurrence during anticoagulationAge (per year) · younger age associated with recurrence | 0.97 (0.95–0.99) | |
| Recurrence after anticoagulation discontinuation, by anticoagulation duration91 to 180 daysvs 30 days or less | 0.49 (0.24–1.00) | |
| Recurrence after anticoagulation discontinuation, by anticoagulation durationMore than 180 daysvs 30 days or less | 0.35 (0.17–0.71) | |
| 0.10.31310Subdistribution hazard ratio (log scale) |
Percent
Lung
6.4%(95% CI 4.0–9.5)
Gastrointestinal
4.0%(95% CI 2.6–6.0)
Genitourinary
3.6%(95% CI 1.6–6.8)
Breast
2.5%(95% CI 1.2–4.5)
Hematologic
1.4%(95% CI 0.5–3.4)
Safety
Factors associated with bleeding during anticoagulation
| sHR (95% CI) | ||
|---|---|---|
| Genitourinary cancer | 4.95 (1.16–21.17) | |
| Transient risk factors | 1.75 (1.16–2.64) | |
| 0.050.21520Subdistribution hazard ratio (log scale) |
Original publication
Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site. JACC CardioOncol. Published June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →